Equillium Inc (EQ)
1.73
+0.06
(+3.59%)
USD |
NASDAQ |
May 06, 10:57
Equillium Cash from Financing (TTM): -9.228M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -9.228M |
September 30, 2023 | -10.66M |
June 30, 2023 | -10.40M |
March 31, 2023 | -2.644M |
December 31, 2022 | -1.215M |
September 30, 2022 | 0.366M |
June 30, 2022 | 0.54M |
March 31, 2022 | 1.097M |
December 31, 2021 | 31.06M |
September 30, 2021 | 30.85M |
Date | Value |
---|---|
June 30, 2021 | 83.74M |
March 31, 2021 | 83.13M |
December 31, 2020 | 53.94M |
September 30, 2020 | 53.83M |
June 30, 2020 | 10.71M |
March 31, 2020 | 10.61M |
December 31, 2019 | 9.836M |
September 30, 2019 | 74.70M |
June 30, 2019 | 64.76M |
March 31, 2019 | 66.36M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-10.66M
Minimum
Sep 2023
83.74M
Maximum
Jun 2021
25.00M
Average
10.61M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Janux Therapeutics Inc | 59.55M |
Mersana Therapeutics Inc | 94.68M |
Vera Therapeutics Inc | 133.54M |
Jasper Therapeutics Inc | 100.97M |
PepGen Inc | -0.189M |